Glow Lifetech Grants Stock Options
Inspira™ Announces Pricing of $3.2M Private Placement by New and Existing Investors of the Company
In-Depth Analysis of BGM Group: Innovating Pharmaceuticals and Insurance through AI
NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study
Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand
Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance...
ZyVersa is advancing a pipeline of first-in-class drug candidates built around two proprietary technologies. - Inflammasome ASC Inhibitor IC 100...
The home-like facility in Southwest Florida is expected to serve 400+ patients each yearFORT MYERS, Fla., Dec. 18, 2024 (GLOBE...
Key preclinical milestone for novel, non-opioid extended-release pain therapeutic SARASOTA, FL, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc....
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Oracle Health partnership enables 400-bed Texas-based health system to leverage RevID’s automated charge reconciliation to improve financial performanceATLANTA, Dec. 18,...
Partnership leverages proprietary PHICS™ technology to bring together a kinase and target of interest to modulate protein function, in this...
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1...
- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials...
FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering...
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational...
BOSTON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform...
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel...
CAMBRIDGE, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate...
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases Tvardi has...
TORONTO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Redecan Cannabis, a leading brand under Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), a...
Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE...
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding...
Investments of up to $50 million from the Bill & Melinda Gates Foundation to develop globally accessible in vivo genetic...
The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer...
